Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 5:34 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 96 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Telangiectasis Clear all
Terminated Phase 2 Interventional Results available

N-Acetyl-L-Leucine for Ataxia-Telangiectasia (A-T)

NCT03759678
View directory record Official record
Conditions
Ataxia Telangiectasia
Interventions
IB1001
Drug
Lead sponsor
IntraBio Inc
Industry
Eligibility
6 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2025
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Mar 24, 2026 · Synced Jul 22, 2026, 5:34 AM EDT
Active, not recruiting Phase 3 Interventional

A Study to Determine the Safety and Efficacy of NT-501 With MHFM

NCT06397131
View directory record Official record
Conditions
Macular Telangiectasia Type 2
Interventions
NT-501 CNTF Implant
Combination Product
Lead sponsor
Neurotech Pharmaceuticals
Industry
Eligibility
21 Years to 80 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2026
U.S. locations
3
States / cities
Walnut Creek, California • Grand Rapids, Michigan • Bellaire, Texas
Source: ClinicalTrials.gov public record
Updated Jul 9, 2025 · Synced Jul 22, 2026, 5:34 AM EDT
Completed Phase 4 Interventional Results available

Intranasal Bevacizumab for HHT-Related Epistaxis

NCT02389959
View directory record Official record
Conditions
HHT, Hereditary Hemorrhagic Telangiectasia, Epistaxis, Nose Bleeds, Nasal Bleeding
Interventions
Bevacizumab, Placebo (Saline)
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 31, 2021 · Synced Jul 22, 2026, 5:34 AM EDT
Completed No phase listed Observational

Graded TTCE for Post-Embolization PAVM Monitoring

NCT02936349
View directory record Official record
Conditions
Hereditary Hemorrhagic Telangiectasia (HHT)
Interventions
Transthoracic Contrast Echocardiogram
Other
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 89 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 7, 2019 · Synced Jul 22, 2026, 5:34 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Treatment of Lower Extremity Spider Veins With Excel V

NCT01362192
View directory record Official record
Conditions
Telangiectasis, Spider Veins
Interventions
532 nm KTP Excel V Laser, manufactured by Cutera, Inc.
Device
Lead sponsor
Cutera Inc.
Industry
Eligibility
21 Years to 70 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Ardmore, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 28, 2015 · Synced Jul 22, 2026, 5:34 AM EDT
Completed Phase 1 Interventional

Study to Test How Well Patients With Advanced Solid Tumors Respond to Treatment With the Elimusertib in Combination With Pembrolizumab, to Find the Optimal Dose for Patients, How the Drug is Tolerated and the Way the Body Absorbs, Distributes and Discharges the Drug

NCT04095273
View directory record Official record
Conditions
Advanced Solid Tumors
Interventions
Elimusertib (BAY1895344), Pembrolizumab (Keytruda®)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2023
U.S. locations
8
States / cities
Palo Alto, California • New Haven, Connecticut • Baltimore, Maryland + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 1, 2024 · Synced Jul 22, 2026, 5:34 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

A Clinical Evaluation of the Treatment of Spider Veins on the Ankles

NCT02754479
View directory record Official record
Conditions
Spider Veins
Interventions
Nd:YAG laser
Device
Lead sponsor
Cutera Inc.
Industry
Eligibility
20 Years to 75 Years
Enrollment
4 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Naperville, Illinois
Source: ClinicalTrials.gov public record
Updated May 8, 2023 · Synced Jul 22, 2026, 5:34 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Effects of PRK 124 Lotion in Acne Rosacea

NCT00580723
View directory record Official record
Conditions
Acne Rosacea
Interventions
PRK 124
Other
Lead sponsor
University of California, Irvine
Other
Eligibility
21 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Jan 16, 2014 · Synced Jul 22, 2026, 5:34 AM EDT
Completed Not applicable Interventional Results available

Study of the 532 nm KTP Laser for the Treatment of Poikiloderma of Civatte

NCT01491620
View directory record Official record
Conditions
Poikiloderma of Civatte, Dyschromia, Pigmentation Disorders, Telangiectasia, Photosensitivity Disorders
Interventions
532 nm KTP laser
Device
Lead sponsor
Cutera Inc.
Industry
Eligibility
35 Years to 65 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Edina, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 27, 2022 · Synced Jul 22, 2026, 5:34 AM EDT
Completed Phase 1 Interventional

Treatment of Vascular Lesions With a Tandem 532/1064 nm Laser

NCT00585338
View directory record Official record
Conditions
Vascular Lesion
Interventions
Tandem 532/1064 nm Laser
Device
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Irvine, California
Source: ClinicalTrials.gov public record
Updated Oct 19, 2022 · Synced Jul 22, 2026, 5:34 AM EDT
Completed No phase listed Observational

Ultra-low-dose Chest CT for HHT

NCT04874558
View directory record Official record
Conditions
Hereditary Hemorrhagic Telangiectasia
Interventions
Ultra-low dose chest CT
Diagnostic Test
Lead sponsor
Mayo Clinic
Other
Eligibility
1 Year to 17 Years
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2026 · Synced Jul 22, 2026, 5:34 AM EDT
Completed Phase 2 Interventional Results available

High-Dose Lucentis (Ranibizumab 2.0mg) for the Treatment of Nonproliferative Idiopathic Parafoveal Telangiectasia

NCT01205035
View directory record Official record
Conditions
Retinal Diseases, Telangiectasis
Interventions
ranibizumab 2.0mg
Drug
Lead sponsor
Eye Center of Northern Colorado, P.C.
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Fort Collins, Colorado
Source: ClinicalTrials.gov public record
Updated Apr 9, 2015 · Synced Jul 22, 2026, 5:34 AM EDT
Completed Phase 1 Interventional

Ciliary Neurotrophic Factor (CNTF) Safety Trial in Patients With Macular Telangiectasia (Mactel)

NCT01327911
View directory record Official record
Conditions
Idiopathic Juxtafoveal Telangiectasia
Interventions
NT-501 implant
Biological
Lead sponsor
Neurotech Pharmaceuticals
Industry
Eligibility
21 Years and older
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
2
States / cities
Los Angeles, California • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 21, 2016 · Synced Jul 22, 2026, 5:34 AM EDT
Withdrawn Phase 1 Interventional

A Trial of TER-1754 in Patients With Hereditary Hemorrhagic Telangiectasia

NCT07255846
View directory record Official record
Conditions
Hereditary Hemorrhagic Telangiectasia (HHT)
Interventions
TER-1754, Placebo
Drug
Lead sponsor
Terremoto Biosciences Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced Jul 22, 2026, 5:34 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics

NCT05692596
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma, Pancreatic Cyst, Chronic Pancreatitis, Fatty Pancreas, Genetic Pancreatic Cancer, Genetic Pancreatitis, BRCA Mutation, Lynch Syndrome, FAP, Familial Atypical Multiple Mole-Melanoma, PALB2 Gene Mutation, Peutz-Jeghers Syndrome, Ataxia Telangiectasia
Interventions
Data collection
Other
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
317 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2026
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 31, 2026 · Synced Jul 22, 2026, 5:34 AM EDT
Completed Phase 1Phase 2 Interventional

Treatment of Exudative and Vasogenic Chorioretinal Diseases Including Variants of AMD and Other CNV Related Maculopathy

NCT00470977
View directory record Official record
Conditions
Coats' Disease, Idiopathic Retinal Telangiectasia, Retinal Angiomatous Proliferation, Polypoidal Choroidal Vasculopathy, Pseudoxanthoma Elasticum, Pathological Myopia, Multi-focal Choroiditis, Rubeosis Iridis, Von Hippel Lindau Disease, BEST VITELLIFORM MACULAR DYSTROPHY, MULTIFOCAL (Disorder)
Interventions
ranibizumab injection (0.5 mg)
Drug
Lead sponsor
Manhattan Eye, Ear & Throat Hospital
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 24, 2012 · Synced Jul 22, 2026, 5:34 AM EDT
Recruiting Phase 1Phase 2 Interventional

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

NCT04657068
View directory record Official record
Conditions
Advanced Cancer, Metastatic Cancer, Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer, Endometrial Cancer, Metastatic Colorectal Cancer, Pancreatic Ductal Adenocarcinoma, Acinar Cell Carcinoma
Interventions
ART0380, Gemcitabine, Irinotecan
Drug
Lead sponsor
Artios Pharma Ltd
Industry
Eligibility
18 Years and older
Enrollment
442 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
40
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Little Rock, Arkansas + 33 more
Source: ClinicalTrials.gov public record
Updated Mar 17, 2026 · Synced Jul 22, 2026, 5:34 AM EDT
Completed Phase 2 Interventional Results available

Evaluation of the Tolerability of Switching Subjects on Chronic ATC Opioid Therapy to Buprenorphine HCl Buccal Film

NCT01871285
View directory record Official record
Conditions
Pain
Interventions
Buprenorphine, Placebo film, Oxycodone, Morphine sulfate, Placebo capsule
Drug
Lead sponsor
BioDelivery Sciences International
Industry
Eligibility
18 Years to 60 Years
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
3
States / cities
Overland Park, Kansas • Philadelphia, Pennsylvania • Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Feb 26, 2017 · Synced Jul 22, 2026, 5:34 AM EDT
Completed Phase 2 Interventional

Thalidomide Reduces Arteriovenous Malformation Related Gastrointestinal Bleeding

NCT00389935
View directory record Official record
Conditions
Arteriovenous Malformation, Hereditary Hemorrhagic Telangiectasia, Hematochezia, Melena
Interventions
Thalidomide
Drug
Lead sponsor
Northport Veterans Affairs Medical Center
Federal
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
3
States / cities
Augusta, Georgia • Worcester, Massachusetts • Northport, New York
Source: ClinicalTrials.gov public record
Updated Aug 1, 2011 · Synced Jul 22, 2026, 5:34 AM EDT
Completed No phase listed Observational

Microvascular Plug (MVP) for the Treatment of Pulmonary ArterioVenous Malformations (PAVMs)

NCT04396041
View directory record Official record
Conditions
Pulmonary Arteriovenous Malformation
Interventions
Microvascular Plug (MVP), Amplatzer Vascular Plug (AVP), Detachable coils
Device
Lead sponsor
Johns Hopkins University
Other
Eligibility
Not listed
Enrollment
223 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jan 31, 2023 · Synced Jul 22, 2026, 5:34 AM EDT
Withdrawn Not applicable Interventional

Laser Therapy Versus Electrosurgery For Nasal Telangiectasias

NCT02090517
View directory record Official record
Conditions
Telangiectasis
Interventions
Pulsed Dye Laser, Long Pulsed Alexandrite Laser, Pulsed Dye Laser Plus Nd:YAG Laser, Electrodesiccation
Device · Procedure
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Jul 22, 2026, 5:34 AM EDT
Completed Phase 3 Interventional Results available

A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol A

NCT03316300
View directory record Official record
Conditions
Macular Telangiectasia Type 2 (MacTel)
Interventions
NT-501, Sham Procedure
Combination Product · Procedure
Lead sponsor
Neurotech Pharmaceuticals
Industry
Eligibility
21 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
16
States / cities
La Jolla, California • Los Angeles, California • Palo Alto, California + 13 more
Source: ClinicalTrials.gov public record
Updated Sep 23, 2024 · Synced Jul 22, 2026, 5:34 AM EDT
Completed No phase listed Observational

Screening Behavior in Adults With Hereditary Hemorrhagic Telangiectasia

NCT00684879
View directory record Official record
Conditions
Osler-Rendu-Weber Disease, Osler-Rendu Disease, Telangiectasia, Hereditary Hemorrhagic
Interventions
Not listed
Lead sponsor
National Human Genome Research Institute (NHGRI)
NIH
Eligibility
18 Years and older
Enrollment
320 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2016
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Jul 22, 2026, 5:34 AM EDT
Completed Phase 1 Interventional

Trial of XRD-0394, a Kinase Inhibitor, in Combination With Palliative Radiotherapy in Advanced Cancer Patients

NCT05002140
View directory record Official record
Conditions
Metastasis, Locally Advanced Solid Tumor, Recurrent Cancer
Interventions
XRD-0394, Palliative radiotherapy
Drug · Radiation
Lead sponsor
XRad Therapeutics Inc
Industry
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
2
States / cities
Stanford, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 10, 2024 · Synced Jul 22, 2026, 5:34 AM EDT